AbCellera Biologics (ABCL) to Announce Quarterly Earnings on Wednesday

AbCellera Biologics (NASDAQ:ABCL) is projected to issue its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect AbCellera Biologics to post earnings of ($0.1186) per share and revenue of $7.8480 million for the quarter. Investors may visit the the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 5:00 PM ET.

AbCellera Biologics (NASDAQ:ABCL) last announced its earnings results on Monday, May 11th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.08. AbCellera Biologics had a negative net margin of 181.75% and a negative return on equity of 14.86%. The company had revenue of $8.31 million for the quarter, compared to analyst estimates of $5.41 million. During the same period in the prior year, the business earned ($0.15) earnings per share. On average, analysts expect AbCellera Biologics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

AbCellera Biologics Trading Up 0.9%

Shares of ABCL traded up $0.04 during mid-day trading on Wednesday, hitting $5.33. 2,060,028 shares of the company traded hands, compared to its average volume of 5,715,693. The stock has a market capitalization of $1.63 billion, a price-to-earnings ratio of -11.11 and a beta of 1.14. The business has a 50-day moving average of $6.12 and a 200 day moving average of $4.59. AbCellera Biologics has a one year low of $2.74 and a one year high of $8.44.

Wall Street Analyst Weigh In

A number of brokerages have commented on ABCL. Weiss Ratings reiterated a “sell (d-)” rating on shares of AbCellera Biologics in a research report on Friday, July 17th. Benchmark raised AbCellera Biologics from a “hold” rating to a “buy” rating and set a $11.00 price target on the stock in a research note on Tuesday, July 7th. JonesTrading started coverage on AbCellera Biologics in a report on Friday, April 10th. They issued a “buy” rating and a $11.00 price target on the stock. Wall Street Zen lowered AbCellera Biologics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Finally, Cantor Fitzgerald initiated coverage on AbCellera Biologics in a report on Tuesday, May 5th. They set an “overweight” rating and a $7.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, AbCellera Biologics has an average rating of “Moderate Buy” and a consensus target price of $8.00.

Hedge Funds Weigh In On AbCellera Biologics

Hedge funds have recently added to or reduced their stakes in the stock. Invesco Ltd. grew its position in shares of AbCellera Biologics by 27.9% during the 4th quarter. Invesco Ltd. now owns 54,603 shares of the company’s stock worth $187,000 after buying an additional 11,914 shares during the period. XTX Topco Ltd acquired a new position in AbCellera Biologics during the fourth quarter valued at approximately $1,242,000. nVerses Capital LLC bought a new stake in AbCellera Biologics in the fourth quarter valued at approximately $121,000. Voloridge Investment Management LLC raised its holdings in AbCellera Biologics by 170.0% in the fourth quarter. Voloridge Investment Management LLC now owns 695,796 shares of the company’s stock worth $2,380,000 after purchasing an additional 438,061 shares during the period. Finally, Virtus Investment Advisers LLC raised its holdings in AbCellera Biologics by 103.4% in the fourth quarter. Virtus Investment Advisers LLC now owns 73,488 shares of the company’s stock worth $251,000 after purchasing an additional 37,365 shares during the period. Institutional investors and hedge funds own 61.42% of the company’s stock.

AbCellera Biologics Company Profile

AbCellera Biologics Inc (NASDAQ: ABCL) is a biotechnology company specializing in the discovery and development of therapeutic antibodies. The company’s technology platform integrates single-cell screening, microfluidics, high-throughput sequencing and artificial intelligence to rapidly identify and optimize antibody candidates against a wide range of disease targets. By combining experimental data with machine learning, AbCellera accelerates early-stage drug discovery and improves the efficiency of lead candidate selection.

AbCellera primarily operates through partnerships with pharmaceutical and biotechnology firms, offering its antibody discovery services on a fee-for-service and milestone-driven basis.